Trevena Announced That Its Partner In China, Jiangsu Nhwa, Received Formal Approval From The National Medical Products Administration For Olinvyk. It Has Been Approved For Use In Adults For The Management Of Acute Pain Severe Enough To Require An Intravenous Opioid Analgesic And For Whom Alternative Treatments Are Inadequate.Olinvyk Is A New Chemical Entity Approved By The Fda In August 2020. Olinvyk Contains Oliceridine, An Opioid, Which Is A Schedule Ii Controlled Substance With A High Potential For Abuse Similar To Other Opioids. It Is Indicated In Adults For The Management Of Acute Pain Severe Enough To Require An Intravenous Opioid Analgesic And For Whom Alternative Treatments Are Inadequate.Olinvyk Is Available In 1 Mg/1 Ml And 2 Mg/2 Ml Single-Dose Vials, And A 30 Mg/30 Ml Single-Patient-Use Vial For Patient-Controlled Analgesia (Pca).The Approval Is Based On Results Of Two Bridging Trials Conducted In China And Also Leveraged Us Clinical Data. Results From The Bridging Studies Demonstrated That The Safety, Tolerability And Pharmacokinetic Profile Of Olinvyk In Chinese Patients Is Consistent With What Has Been Seen In Other Olinvyk Clinical Trials. Jiangsu Nhwa Has An Exclusive Licence Agreement For The Development And Commercialisation Of Olinvyk In China.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!